BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 20519274)

  • 21. The relationship between proangiogenic gene expression levels in prostate cancer and their prognostic value for clinical outcomes.
    Mori R; Dorff TB; Xiong S; Tarabolous CJ; Ye W; Groshen S; Danenberg KD; Danenberg PV; Pinski JK
    Prostate; 2010 Nov; 70(15):1692-700. PubMed ID: 20564320
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The inhibitory effects of gossypol on human prostate cancer cells-PC3 are associated with transforming growth factor beta1 (TGFbeta1) signal transduction pathway.
    Jiang J; Sugimoto Y; Liu S; Chang HL; Park KY; Kulp SK; Lin YC
    Anticancer Res; 2004; 24(1):91-100. PubMed ID: 15015581
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of the dual 5 alpha-reductase inhibitor dutasteride on apoptosis in primary cultures of prostate cancer epithelial cells and cell lines.
    Maria McCrohan A; Morrissey C; O'Keane C; Mulligan N; Watson C; Smith J; Fitzpatrick JM; Watson RW
    Cancer; 2006 Jun; 106(12):2743-52. PubMed ID: 16703599
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Steroid 5alpha-reductase isozymes I and II in recurrent prostate cancer.
    Titus MA; Gregory CW; Ford OH; Schell MJ; Maygarden SJ; Mohler JL
    Clin Cancer Res; 2005 Jun; 11(12):4365-71. PubMed ID: 15958619
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Regulation of androgen receptor transactivity and mTOR-S6 kinase pathway by Rheb in prostate cancer cell proliferation.
    Kobayashi T; Shimizu Y; Terada N; Yamasaki T; Nakamura E; Toda Y; Nishiyama H; Kamoto T; Ogawa O; Inoue T
    Prostate; 2010 Jun; 70(8):866-74. PubMed ID: 20127734
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CCR2 expression correlates with prostate cancer progression.
    Lu Y; Cai Z; Xiao G; Liu Y; Keller ET; Yao Z; Zhang J
    J Cell Biochem; 2007 Jun; 101(3):676-85. PubMed ID: 17216598
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of human prostate cancer xenograft growth by 125I labeled triple-helix forming oligonucleotide directed against androgen receptor.
    Zhang Y; Ma Y; Lu HP; Gao JH; Liang CS; Liu CZ; Zou JT; Wang HQ
    Chin Med J (Engl); 2008 Nov; 121(22):2284-9. PubMed ID: 19080333
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gene expression of angiogenic factors correlates with metastatic potential of prostate cancer cells.
    Aalinkeel R; Nair MP; Sufrin G; Mahajan SD; Chadha KC; Chawda RP; Schwartz SA
    Cancer Res; 2004 Aug; 64(15):5311-21. PubMed ID: 15289337
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gene expression in the LNCaP human prostate cancer progression model: progression associated expression in vitro corresponds to expression changes associated with prostate cancer progression in vivo.
    Chen Q; Watson JT; Marengo SR; Decker KS; Coleman I; Nelson PS; Sikes RA
    Cancer Lett; 2006 Dec; 244(2):274-88. PubMed ID: 16500022
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The peroxisome proliferator-activated receptor gamma ligand 15-deoxy-Delta12,14-prostaglandin J2 induces vascular endothelial growth factor in the hormone-independent prostate cancer cell line PC 3 and the urinary bladder carcinoma cell line 5637.
    Haslmayer P; Thalhammer T; Jäger W; Aust S; Steiner G; Ensinger C; Obrist P
    Int J Oncol; 2002 Oct; 21(4):915-20. PubMed ID: 12239635
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of gene expression in LNCaP prostate cancer cells after treatment with bicalutamide or 5-alpha-reductase inhibitors.
    Bühler P; Fischer T; Wolf P; Gierschner D; Schultze-Seemann W; Wetterauer U; Elsässer-Beile U
    Urol Int; 2010; 84(2):203-11. PubMed ID: 20215827
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thrombin receptor expression is upregulated in prostate cancer.
    Kaushal V; Kohli M; Dennis RA; Siegel ER; Chiles WW; Mukunyadzi P
    Prostate; 2006 Feb; 66(3):273-82. PubMed ID: 16245281
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer.
    Tindall DJ; Rittmaster RS
    J Urol; 2008 Apr; 179(4):1235-42. PubMed ID: 18280514
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Suppression of VEGF-mediated autocrine and paracrine interactions between prostate cancer cells and vascular endothelial cells by soy isoflavones.
    Guo Y; Wang S; Hoot DR; Clinton SK
    J Nutr Biochem; 2007 Jun; 18(6):408-17. PubMed ID: 17142033
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prostate cancer cells regulate growth and differentiation of bone marrow endothelial cells through TGFbeta and its receptor, TGFbetaRII.
    Barrett JM; Rovedo MA; Tajuddin AM; Jilling T; Macoska JA; MacDonald J; Mangold KA; Kaul KL
    Prostate; 2006 May; 66(6):632-50. PubMed ID: 16388503
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer.
    Luo J; Zha S; Gage WR; Dunn TA; Hicks JL; Bennett CJ; Ewing CM; Platz EA; Ferdinandusse S; Wanders RJ; Trent JM; Isaacs WB; De Marzo AM
    Cancer Res; 2002 Apr; 62(8):2220-6. PubMed ID: 11956072
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Changes in retinal gene expression in proliferative vitreoretinopathy: glial cell expression of HB-EGF.
    Hollborn M; Tenckhoff S; Jahn K; Iandiev I; Biedermann B; Schnurrbusch UE; Limb GA; Reichenbach A; Wolf S; Wiedemann P; Kohen L; Bringmann A
    Mol Vis; 2005 Jun; 11():397-413. PubMed ID: 15988409
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prostate cancer stromal cells and LNCaP cells coordinately activate the androgen receptor through synthesis of testosterone and dihydrotestosterone from dehydroepiandrosterone.
    Mizokami A; Koh E; Izumi K; Narimoto K; Takeda M; Honma S; Dai J; Keller ET; Namiki M
    Endocr Relat Cancer; 2009 Dec; 16(4):1139-55. PubMed ID: 19608712
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Conversion of prostate cancer from hormone independency to dependency due to AMACR inhibition: involvement of increased AR expression and decreased IGF1 expression.
    Takahara K; Azuma H; Sakamoto T; Kiyama S; Inamoto T; Ibuki N; Nishida T; Nomi H; Ubai T; Segawa N; Katsuoka Y
    Anticancer Res; 2009 Jul; 29(7):2497-505. PubMed ID: 19596919
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Smad3 is overexpressed in advanced human prostate cancer and necessary for progressive growth of prostate cancer cells in nude mice.
    Lu S; Lee J; Revelo M; Wang X; Lu S; Dong Z
    Clin Cancer Res; 2007 Oct; 13(19):5692-702. PubMed ID: 17908958
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.